Zrepag 2mg Tablet contains Repaglinide, a meglitinide class oral hypoglycemic agent used in the management of type 2 diabetes mellitus. Repaglinide acts by stimulating pancreatic beta cells to release insulin, thereby reducing postprandial blood glucose levels. It is particularly effective in controlling blood sugar spikes after meals and is indicated for patients whose diabetes is not adequately controlled by diet and exercise alone. Zrepag should be administered shortly before meals to optimize glycemic control. The dosage must be individualized based on the patient’s glycemic response, with careful monitoring to minimize the risk of hypoglycemia, the most common adverse effect. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or hypersensitivity to Repaglinide or any excipients. Caution is advised in patients with hepatic or renal impairment, and concomitant use with other antidiabetic agents should be supervised by a healthcare professional. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy and adjust dosing accordingly. Zrepag 2mg Tablet is a valuable option for improving glycemic control in type 2 diabetes when used as part of a comprehensive treatment plan including diet, exercise, and lifestyle modification.